Shares of RAPT Therapeutics (NASDAQ:RAPT) plunged 46% in early trading Monday after the company said it was scrapping ...
Removing zelnecirnon means the biotech’s sole remaining clinical-stage asset is tivumecirnon, a phase 2 oncology med being ...
Rapt Therapeutics Inc ( (RAPT) ) has released its Q3 earnings. Here is a breakdown of the information Rapt Therapeutics Inc presented to its ...
"RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull" was originally created and published by Clinical ...
RAPT Therapeutics stock falls after halting its zelnecirnon program following FDA clinical hold. Company shifts focus.
In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rating on RAPT Therapeutics (RAPT – Research Report), with a price target of $4.00. Yanan Zhu’s rating is based on RAPT ...
In February 2024, the FDA put two Phase II studies of zelnecirnon under a clinical hold after a case of liver failure was deemed potentially related to the drug.
Shares of RAPT Therapeutics touched an all-time low following news the company terminated its zelnecirnon program after feedback from the Food and Drug Administration. In the last hour of Monday's ...
RAPT Therapeutics has ended its zelnecirnon program following safety concerns raised by the FDA after a severe adverse event ...
The South San Francisco, Calif., biopharmaceutical company in May shut down two trials of zelnecirnon, which was being evaluated as a treatment for asthma and atopic dermatitis.
Shares of RAPT Therapeutics (NASDAQ:RAPT) plunged 46% in early trading Monday after the company said it was scrapping development of its drug candidate zelnecirnon due to negative FDA feedback.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback